Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IXICOLSE:IXI Days Sales Outstanding is 83.72 as of Mar. 2026, which is 14% below its 10-year median of 97.07. The stock has 2 warning signs investors should review. Among 841 Biotechnology companies, IXICO ranks worse than 61.95% on this metric.
IXICO's average Accounts Receivable for the
six
months ended in Mar. 2026 was £1.81 Mil. IXICO's Revenue for the
six
months ended in Mar. 2026 was £3.95 Mil.
Hence, IXICO's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 83.72.
The historical rank and industry rank for IXICO's Days Sales Outstanding or its related term are showing as below:
LSE:IXI'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 79.36 Med: 97.07 Max: 122.8
Current: 86.98
During the past 13 years, IXICO's highest Days Sales Outstanding was 122.80. The lowest was 79.36. And the median was 97.07.
LSE:IXI's Days Sales Outstanding is ranked worse than 61.95% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs LSE:IXI: 86.98
IXICO's Days Sales Outstanding
declined
from Mar. 2025 (91.36) to Mar. 2026 (83.72).
IXICO (LSE:IXI) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
IXICO Days Sales Outstanding Related Terms
IXICO Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for IXICO's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:IXI vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, IXICO's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IXICO Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IXICO's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where IXICO's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IXICO (LSE:IXI) has a Days Sales Outstanding of 83.72 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on IXICO and its competitors. This is 14% below median its historical median of 97.07. Over the past decade, IXICO's Days Sales Outstanding has ranged from 79.36 to 122.80. According to the industry distribution chart, IXICO ranks #521 out of 841 companies in the Biotechnology industry, placing it in the top 62%.
Is IXICO's Days Sales Outstanding too high?
IXICO's current Days Sales Outstanding of 83.72 is 14% below median its 10-year median of 97.07. Over the past 10 years, this metric has ranged from a low of 79.36 to a high of 122.80. The Biotechnology industry median Days Sales Outstanding is 68.98. IXICO's value of 83.72 is 21.4% above this industry median. Based on the distribution chart, IXICO ranks #521 out of 841 companies in the Biotechnology industry, which is below the industry midpoint.
How does IXICO's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IXICO ranks #521 out of 841 companies for Days Sales Outstanding. This places IXICO in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. IXICO's value of 83.72 is 21.4% above this benchmark. Historically, IXICO's own Days Sales Outstanding has ranged from 79.36 to 122.80 over the past decade. While the company's 10-year median is 97.07 vs. the industry median of 68.98, IXICO has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IXICO's current Days Sales Outstanding of 83.72 is 21.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on IXICO and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IXICO's current Days Sales Outstanding is 83.72, which is 14% below median its own 10-year median of 97.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IXICO stock overvalued right now?
Based on GuruFocus' analysis, IXICO (LSE:IXI) is currently considered Fairly Valued. The stock's GF Value™ is £0.08, compared to a current price of £0.08 — trading 6.3% below its estimated fair value. The current Days Sales Outstanding is 83.72, which is 14% below median its 10-year median of 97.07 and 21.4% above the Biotechnology industry median of 68.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For IXICO (LSE:IXI), the current Days Sales Outstanding is 83.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IXI has been successfully added to your 
